Lantern Pharma (NASDAQ: LTRN) has positioned itself at the center of an industry-wide call to reform what biotech leaders describe as a broken drug development model. The Dallas-based clinical-stage biopharmaceutical company was highlighted in coverage of the 2025 BioNTX iC3 Summit, where CEO Panna Sharma served as both moderator and panelist advocating for technological transformation.
Sharma articulated the core challenge facing the industry, stating that the drug development process remains largely manual despite available technological solutions. The CEO emphasized that AI-driven platforms like Lantern Pharma's RADR system can streamline discovery, accelerate clinical timelines, and significantly reduce costs. This approach directly addresses the summit's central theme of creating a more sustainable and efficient future for biotechnology.
The full coverage of the summit and Sharma's comments can be found at https://ibn.fm/DM9ur. Lantern Pharma's RADR AI platform represents a fundamental shift in how oncology drugs are developed, leveraging over 200 billion oncology-focused data points and a library of more than 200 machine learning algorithms. This data-driven approach aims to solve what the company describes as billion-dollar problems in oncology drug development.
The implications of this industry shift are substantial for both healthcare economics and patient outcomes. Traditional drug development can take over a decade and cost billions of dollars, with high failure rates that ultimately drive up healthcare costs. AI-driven approaches could potentially compress development timelines and improve success rates, making innovative treatments more accessible and affordable. For investors and industry observers, the latest developments from Lantern Pharma are available in the company's newsroom at https://ibn.fm/LTRN.
Lantern Pharma's growing pipeline includes a Phase 2 clinical program and multiple Phase 1 clinical trials spanning both solid tumors and blood cancers, with an estimated combined annual market potential exceeding $15 billion. The company's approach represents a broader movement within biotech to leverage artificial intelligence and machine learning to address longstanding inefficiencies. As the industry grapples with the challenges of sustainable drug development, companies like Lantern Pharma are demonstrating how technology can create more predictable and cost-effective pathways from discovery to patient treatment.
